Search research articles
Contact Us
Filters
Showing results (91-100 of 133) with videos related to
Page
of 14
Sort By:
Haematologica
|
January 2, 2008
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension
Kenneth I Ataga, Charity G Moore, Cheryl A Hillery, et al.
Pediatric Blood & Cancer
|
July 21, 2021
Transition care continuity promotes long-term retention in adult care among young adults with sickle cell disease
Kristen E Howell, Anjelica C Saulsberry-Abate, Joacy G Mathias, et al.
British Journal of Haematology
|
January 13, 2011
Association of soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis in sickle cell disease
Kenneth I Ataga, Julia E Brittain, Susan K Jones, et al.
British Journal of Haematology
|
February 18, 2011
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)
Kenneth I Ataga, Marvin Reid, Samir K Ballas, et al.
British Journal of Haematology
|
October 30, 2015
Coagulation activation in sickle cell trait: an exploratory study
Chirag Amin, Soheir Adam, Micah J Mooberry, et al.
Haematologica
|
May 2, 2024
Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia
Rima S Zahr, Sara R Rashkin, Maria Armila Ruiz, et al.
Blood Advances
|
January 11, 2024
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel
Deva Sharma, Ilknur Kozanoğlu, Kenneth I Ataga, et al.
The Lancet. Haematology
|
April 10, 2021
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial
Jo Howard, Kenneth I Ataga, Robert C Brown, et al.
Blood
|
January 15, 2008
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
Kenneth I Ataga, Wally R Smith, Laura M De Castro, et al.
Plos One
|
September 27, 2016
Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia
Kenneth I Ataga, Vimal K Derebail, Melissa Caughey, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 133) with videos related to
Sort By:
Page
of 14
Haematologica
|
January 2, 2008
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension
Kenneth I Ataga, Charity G Moore, Cheryl A Hillery, et al.
Pediatric Blood & Cancer
|
July 21, 2021
Transition care continuity promotes long-term retention in adult care among young adults with sickle cell disease
Kristen E Howell, Anjelica C Saulsberry-Abate, Joacy G Mathias, et al.
British Journal of Haematology
|
January 13, 2011
Association of soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis in sickle cell disease
Kenneth I Ataga, Julia E Brittain, Susan K Jones, et al.
British Journal of Haematology
|
February 18, 2011
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)
Kenneth I Ataga, Marvin Reid, Samir K Ballas, et al.
British Journal of Haematology
|
October 30, 2015
Coagulation activation in sickle cell trait: an exploratory study
Chirag Amin, Soheir Adam, Micah J Mooberry, et al.
Haematologica
|
May 2, 2024
Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia
Rima S Zahr, Sara R Rashkin, Maria Armila Ruiz, et al.
Blood Advances
|
January 11, 2024
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel
Deva Sharma, Ilknur Kozanoğlu, Kenneth I Ataga, et al.
The Lancet. Haematology
|
April 10, 2021
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial
Jo Howard, Kenneth I Ataga, Robert C Brown, et al.
Blood
|
January 15, 2008
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
Kenneth I Ataga, Wally R Smith, Laura M De Castro, et al.
Plos One
|
September 27, 2016
Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia
Kenneth I Ataga, Vimal K Derebail, Melissa Caughey, et al.
Page
of 14